Abstract:The growing use of molecular imaging helps to control and monitor dosage for increased safety and effectiveness. Molecular imaging agents become the scientific tools for moving a concept from bench work to clinic product development. This special issue provides original research and review of new trends in molecular imaging agent development. Among clinic molecular imaging modalities, radionuclide imaging technique is the most sensitive and could provide target-specific information. The radiotracer could non-invasively assess disease treatment endpoints which used to rely almost exclusively on biopsies and histopathological assays. L.-H. Shen et al. (Taiwan) reviewed molecular imaging in the diagnosis and management of CNS disorders. F.-L. Kong et al. (USA), N. Tsao et al. (USA), and C.-L. Ho et al. (Taiwan) report pharmacokinetics and dosimetry of molecular imaging compounds in oncology. M.-H. Liao et al. (Taiwan), X. Wang et al. (China), C. Wu et al. (China) and M. Tian et al. (USA) reported that molecular imaging techniques play a major role in the development of novel therapies since they measure target expressions (apoptosis, glycolysis) as well as function, pathway activities, and cell migration in the intact organism. Y.-F. Wang et al. and M.-Y. Chao et al. (Taiwan) described the kit probe for 99mTc-labeling which is crucial for centralized drug process. The kit probe may allow theranostic concept. A theranostic agent would be more accurate in the evaluation of patient response to treatment. The radiotracer could also be used for radionuclide therapy as reported by C. Wang et al. (China). Hybrid molecular imaging modalities (PET/CT, SPECT/CT) provide high-sensitivity functional and high-resolution anatomical imaging which are important in design-personalized treatment. M.-C. Chen et al. (Taiwan) reported the value of using I-131 NP-59 SPECT/CT to diagnose patients with subclinical or atypical features of primary aldosteronism. To proof of concept for molecular biology findings using different imaging modalities (optical, sonography) were described by Z. Pu et al. (China). In summary, molecular imaging enables the comprehensive characterization of therapeutic intervention and can be used in preclinical studies, pharmacokinetic studies, dose-finding studies, and proof-of-concept studies. Molecular imaging technologies promote the discovery and development of personalized medicine. Hong Zhang Mei Tian Carrio Ignasi Zhen Cheng Lie-Hang Shen David J. Yang

Using Molecular Imaging Techniques to Study Protein-Protein Interactions

Advances of study of protein-protein interactions

Differently Tagged Probes for Protein Profiling of Mitochondria

Molecular Image-Guided Theranostic and Personalized Medicine 2013

Recent Advances in Mass Spectrometry-based Protein Interactome Studies

Molecular imaging: design mechanism and bioapplications

Application of Twin‐Strep Tagging and TurboID Proximity Labeling in Discovery of Microprotein‐protein Interactions

Molecular-genetic imaging based on reporter gene expression

Identifying The Proteins To Which Small-Molecule Probes And Drugs Bind In Cells

Current Experimental Methods for Characterizing Protein-Protein Interactions.

Protein microarrays for studies of drug mechanisms and biomarker discovery in the era of systems biology.

Imaging mRNA and protein interactions within neurons

Recent progress in mass spectrometry proteomics for biomedical research

Experimental Methods for Characterizing Protein-Protein Interactions

Integrating gene and protein expression data: pattern analysis and profile mining

Profiling cellular protein complexes by proximity ligation with dual tag microarray readout

Mass spectrometry-based metabolomics, analysis of metabolite-protein interactions, and imaging

Proteomic dissection of biological pathways/processes through profiling protein-protein interaction networks

Proteomics and Precision Medicine

Multidimensional Cross-Linking and Real-Time Informatics for Multiprotein Interaction Studies

Mass spectrometry‐based protein–protein interaction networks for the study of human diseases